Novartis trial win lifts profile of new breast cancer drug
Novartis’s efforts to tackle an elusive gene mutation behind tough-to-treat breast cancer were rewarded on Thursday, as the Swiss drugmaker said one of its investigational medicines slowed disease progression.
nalysts said the drug, called BYL719, is on a trajectory to take a leading role in advanced breast cancer treatment.
Novartis said its drug combined with hormone therapy improved progression-free survival in breast cancer patients whose tumors had hormone receptors but not so-called HER2 proteins.
To read the full article, click HERE
REUTERS/Arnd Wiegmann/File Photo